dx 8951 has been researched along with rubitecan in 4 studies
| Studies (dx 8951) | Trials (dx 8951) | Recent Studies (post-2010) (dx 8951) | Studies (rubitecan) | Trials (rubitecan) | Recent Studies (post-2010) (rubitecan) |
|---|---|---|---|---|---|
| 73 | 18 | 15 | 149 | 34 | 22 |
| Protein | Taxonomy | dx 8951 (IC50) | rubitecan (IC50) |
|---|---|---|---|
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 5.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bigg, DC; Lavergne, O | 1 |
| Bailly, C; Lansiaux, A | 1 |
| Takimoto, CH | 1 |
| Herzog, TJ; Wethington, SL; Wright, JD | 1 |
2 review(s) available for dx 8951 and rubitecan
| Article | Year |
|---|---|
[The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Macromolecular Substances; Mice; Molecular Structure; Neoplasm Proteins; Prodrugs; Structure-Activity Relationship; Topoisomerase I Inhibitors | 1998 |
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2008 |
2 other study(ies) available for dx 8951 and rubitecan
| Article | Year |
|---|---|
[A symphony for the camptothecins].
Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan | 2003 |
Are there any better camptothecins than the ones we have?
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance, Neoplasm; Humans; Irinotecan; Pancreatic Neoplasms; Research; Topoisomerase I Inhibitors | 2003 |